Citius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-Lok
(RTTNews) - Biopharmaceutical company Citius Pharmaceuticals, Inc. (CTXR) announced Tuesday positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI).
The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.
The company said it looks forward to engage with the US Food and Drug Administration (FDA) to determine the optimal path forward for Mino-Lok, which is expected to offer a much-needed alternative to the current practice of catheter removal and replacement.
RBI Shifts To 'Calibrated Tightening' As Rate-Hiking Cycle Begins
Indian Rupee Falls To Record Low After RBI Rate Decision
U.S. Dollar Rises As Trader's Focus On U.S. Fed Minutes
U.S. Dollar Rises Against Majors
Yen Rises After BoJ Sato's Hawkish Remarks
Bay Street Likely To Open On Weak Note
Yen Rises Against Majors
